2026-07-01 11:52:57 am | Source: PR Agency
Morepen starts commercial supplies under its Rs 825 Crore CDMO mandate
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced ?825 crore CDMO mandate. The first commercial dispatch, valued at approximately ?50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.
Commenting on the development, Mr. Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, “This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”
Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately ?225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements.
The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.
The commencement of commercial supplies under this mandate reinforces Morepen’s strategy to build a scalable CDMO platform, deepen customer partnerships and participate in long-duration global manufacturing opportunities.
Above views are of the author and not of the website kindly read disclaimer
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Anjali Mudra: A Simple Yoga Gesture That Helps Stren...
FIFA WC: Perfect Mexico blank Ecuador for first knoc...
GST collections rise 14 pc to Rs 1.95 lakh crore in ...
ACME Solar Holdings soars on commissioning 240.720 M...
Mahindra & Mahindra reports 37 pc rise in June sales...
India's manufacturing PMI at 54.2 in June as sector ...
Rupee weakens against US dollar in early trade on We...
India's financial system remains resilient supported...
June manufacturing growth slows to 54.2 despite soft...
Bank credit to industry registers 17.5% growth in Ma...
